FOLR2 and acute leukemia of ambiguous lineage: One such example developed by Lu et al. is an FRβ-targeted liposomal doxorubicin for treating biphenotypic acute leukaemia (BAL).66 The group prepared several FRβ-targeted liposomes (f-L-DOX) and varied the mole percentage of FRβ-targeted distearoyl phosphatidylethanolamine (f-PEG-DSPE) in order to assess which lipid analogue constitutes the optimal formulation for therapeutic activity.66